• [Translate to English:] M.blue Shunt
  • [Translate to English:] MyHCandME App - Patiententagebuch
  • Articles
  • Shunt infection: How it develops and how it can be prevented
    • Shunt therapy is the most common treatment for hydrocephalus, but carries the risk of serious complications such as shunt infections. Find out more about symptoms, causes, treatment options and preventive approaches such as antibiotic-impregnated catheters.
  • LP shunt vs. VP shunt
    • The choice between LP and VP shunt is essential for the successful treatment of hydrocephalus. This article provides a detailed comparison, looking at the indications, benefits and potential risks of both types of implantation - informed insights for better treatment decisions.
  • The measurement of intracranial pressure (ICP)
    • The measurement and interpretation of intracranial pressure (ICP) is a very helpful aid in the diagnosis and treatment of many brain diseases. The article explains the technical requirements for ICP measurements, the interpretation of ICP values in intracranial pressure measurements and their significance for effective treatment planning.
  • The Innovative Leap to Telemetric Pressure Sensors
    • Telemetric pressure sensors are setting new standards in the hydrocephalus shunt therapy. The article analyzes the technical limitations of conventional ICP sensors and presents trend-setting innovations in the field of measurement with telemetric pressure sensors - for more precise and efficient treatments.
  • Over- and underdrainage - the most common “side effects” of shunt systems
    • Shunt systems in hydrocephalus therapy have a long history, but over- and underdrainage are still common complications with their potential consequences, such as slit ventricle syndrome. The article looks at the causes, consequences and therapeutic approaches of both problems and discusses whether gravitational technology offers a possible remedy.
  • Foundations of fluid mechanics, or of beakers, bottles and people
    • The article introduces fluid mechanics and explains how the cerebrospinal fluid works in the human brain. It explains the hydrodynamics in the shunt system and shows why the circulation and pressure of the cerebrospinal fluid are important factors for optimizing shunt therapies.
Young woman crosses her arms in front of her chest

XABO®

Xtra Protection

AGAINST INFECTION

XABO
FEATURES
STORIES
Download
Contact
References
Antibiotic-impregnated catheter and ventricular catheter

XABO®

FEATURES

XABO is an antibiotic-impregnated catheter for hydrocephalus treatment.

  • effective control of gram-positive bacteria1
  • proven reduction of the risk of shunt infections with catheters of this type2
  • continuous release of antibiotics for at least 38 days3
  • long shelf life up to 36 months4
  • positive influence resources time and cost through prevention of shunt infections2
  • available in configuration with selected MIETHKE valves

STORIES

[Translate to English:]

XABO in Action – Zone of Inhibition Testing

A Zone of Inhibition Test is a quick and effective way to assess the antimicrobial activity of a material. Such tests are integral parts of research and development.

The BASICS trial easily explained

The BASICS trial is a clinical study that analyzed the safety and efficacy of antibiotic impregnated catheters.

About bacteria and protective shields

How do shunts get infected and what can we do about that? Lucas and Tom introduce us to the world of bacteria, infection prevention and antibiotics.

[Translate to English:]

Why is XABO orange?

A good question with a simple answer:
It´s the antibiotics.

REDUCE SHUNT INFECTIONS – PREVENT COMPLICATIONS

Implantation of a shunt system consisting of a valve and catheter is the most commonly selected treatment method for hydrocephalus. One of the most common and serious complications associated with this procedure is infection of the surrounding tissue, particularly in the first few weeks after implantation. This affects patients of all ages and can limit their quality of life.2 If infection occurs, the entire shunt system usually has to be removed, followed by antibiotic treatment and later reimplantation of a shunt.

The use of antibiotic-impregnated catheters such as XABO allows this very critical complication to be addressed and reduced in frequency.

 

XABO®

FUNCTIONALITY

XABO catheters are treated with antimicrobial agents during production, allowing them to release antibiotics into the surrounding tissue after implantation. Such antibiotic-impregnated catheters can prevent two-thirds of shunt infections.2

 

Diagram: Proportion of gram-positive bacteria, shelf life up to 36 months

Silicone catheters are impregnated with a balanced mixture of the two antibiotics clindamycin hydrochloride and rifampicin, which effectively control gram-positive bacteria.1 After implantation, the antibiotics are delivered continuously for at least 38 days.3 This period corresponds to the timeframe when patients are most susceptible to infection.5-8 During this time, only a small dose of antibiotics is released locally.

 

Long shelf life, gentle sterilization

In addition to the antimicrobial effect, XABO was designed to simplify transport and storage. The catheters can be stored for up to 36 months and withstand temperatures up to 30 °C (86 °F) without reducing their efficacy.4 The gentle sterilization process and specially designed packaging minimize degradation products and maintain the initial antibiotic load for a prolonged period of time.9

 

M.blue plus with XABO catheter

 

 

CONFIGURATIONS

XABO is available in configurations with selected MIETHKE valves:
These include adjustable valves such as the M.blue, M.blue plus and proGAV 2.0, as well as the preset valve GAV 2.0. These valves are offered in various combinations with shunt components such as the CONTROL RESERVOIR or SPRUNG RESERVOIR. Alternatively, XABO catheters can be purchased individually or as a catheter set and combined with a MIETHKE valve of choice.

 

 

 

XABO

Product downloads

 

Download Area

 

This might also interest you

[Translate to English:]

M.blue & M.blue plus

THE BALANCED WAY OF LIFE
INSPIRED BY YOU

proGAV 2.0 Hydrocephalus shunt

proGAV 2.0

The proGAV 2.0 is a position-dependent hydrocephalus valve. It consists of an adjustable differential pressure unit and a gravitational unit.

[Translate to English:]

Tunneller

DO YOU HAVE ANY QUESTIONS ABOUT THE PRODUCT?
WE ARE THERE FOR YOU

+49 331 620 83 0
info@miethke.com

Thoralf Knitter

Abteilungsleitung Product Development

Roland Schulz

Abteilungsleitung Product Management

Thammo Weise

Product Management

Andreas Bunge

Product Management

Michaela Funk-Neubarth

Leitung Marketing

Jan Mügel

Product Management

Josefine Kehl

Stellvertretende Leitung Marketing & Unternehmenskommunikation

August von Hardenberg

Referent Geschäftsführung

Please input the following security code.

Captcha image

Your data will only be used for strictly appropriated processing and for answering your request. This consent can be revoked at any time by a message to us. In case of cancellation your data will be deleted immediately. Further information can be found in the privacy policy.

Fields marked with * are mandatory

Patients and engineers together

OUR PARTNERSHIP
WITH B. BRAUN

B. Braun and MIETHKE - Together for a better life with hydrocephalus

 

We have a long and intensive partnership with B. Braun in the field of neurosurgery. We are driven by a common vision: to improve the lives of hydrocephalus patients around the world with innovative solutions.

Our partnership is an exciting combination of B. Braun's nearly 180 years of expertise as one of the world's leading medical device and pharmaceutical companies and our agility as an innovative company and technology leader in gravitation-based shunt technology. 

 

Our strong partner in neurosurgery:

www.bbraun.com

References

  1. MIETHKE report. Data on file.
  2. Mallucci CL, Jenkinson MD, Conroy EJ, et al. Antibiotic or silver versus standard ventriculoperitoneal shunts (BASICS): a multicentre, single-blinded, randomised trial and economic evaluation. The Lancet 2019;394(10208):1530–39.
  3. MIETHKE report. Data on file.
  4. MIETHKE report. Data on file.
  5. Borgbjerg BM, Gjerris F, Albeck MJ, Børgesen SE. Risk of infection after cerebrospinal fluid shunt: an analysis of 884 first-time shunts. Acta Neurochir (Vienna). 1995;136(1-2):1-7.
  6. George R, Leibrock L, Epstein M. Long-term analysis of cerebrospinal fluid shunt infections. A 25-year experience. J Neurosurg. 1979;51(6):804-811.
  7. Okamura Y, Maruyama K, Fukuda S, et al. Detailed standardized protocol to prevent cerebrospinal fluid shunt infection. J Neurosurg. 2019;132(3):755-759. Published 2019 Feb 15.
  8. Wells DL, Allen JM. Ventriculoperitoneal shunt infections in adult patients. AACN Adv Crit Care. 2013;24(1):6-14.
  9. MIETHKE report. Data on file.